Drug intelligence / Profile preview

BI 3776528

Development stage: Phase 1
Lead developer: Boehringer

Overview

BI 3776528 is an investigational drug developed by Boehringer Ingelheim. As of mid-2025, it is a new molecular entity with an undisclosed mechanism of action and therapeutic indication. The compound is currently being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. No information about its target(s), modality, or specific disease focus has been publicly disclosed[3][4][7]. The drug does not have orphan designation and has not received regulatory approval for any indication.

Beyond the preview

Go deeper on BI 3776528.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3776528.

Explore the full profile